Global Protein Therapeutics Market: Overview
The global market for protein therapeutics has witnessed a significant rise in application in the treatment of a number of genetic, rare, and life-threatening diseases. It is known that proteins are crucial for maintaining a healthy lifestyle and people, whose bodies cannot produce or break down some essential proteins naturally, are prone to several diseases. The rising global prevalence of diabetes for instance, a disease that is caused due to dysfunctional production or processing of the protein insulin, has led to significant developments in the global protein therapeutics market in the past few years.
This report on the global protein therapeutics market presents a detailed analysis of the market and its key segments in the present scenario. The report examines the market across several regional markets and includes an analysis of the key factors driving and restraining the growth of the market. An analysis of key trends of the past and present years, which have helped shape the market’s present dynamics, is also included.
Global Protein Therapeutics Market: Drivers and Restraints
One of the key factors fueling the growth prospects of the global protein therapeutics market is the vast rise in the rate of incidence of a number of chronic diseases such as cancer, cardiovascular conditions, and diabetes. The market is also driven due to the increased awareness among consumers regarding the high efficiency of protein therapeutics with the minimum risk of side effects and the increased level of acceptance among end users. However, the market’s growth prospects are retrained to a certain extent owing to the vast funds required to undertake research and develop efficient methods for studying complex biological systems that can simulate the target organs or tissues.
Global Protein Therapeutics Market: Segmentation
The market for protein therapeutics is segmented in the report broadly on the basis of criteria such as protein therapeutic modalities, product variety, application, indication, and geography. The key protein therapeutic modalities include protein diagnostics, protein vaccines, protein therapeutics with special targeting activity, and protein therapeutics with enzymatic or regulatory activity. Key product varieties in the protein therapeutics market include insulin, monoclonal antibodies (mAbs), and blood clotting agents. Key indications making extensive usage of protein therapeutics include neurological disorders, diabetes, genetic disorders, and cancer.
Global Protein Therapeutics Market: Geographical and Competitive Dynamics
On the basis of geography, the global protein therapeutics market has been categorized in the report into regions such as Latin America, Europe, North America, Middle East, and Africa. These regions are further segmented and analyzed according to the key countries contributing significantly to the development of the protein therapeutics market across these regions. Aspects such as regulatory framework of these regions surrounding the field of protein therapeutics, the process of approval protein therapeutics products, and the overall growth prospects of the market across each of these regions and countries are examined in the report.
The report also includes an elaborate section analyzing the competitive landscape of the global protein therapeutics market. With the help of a Porter’s five forces analysis, the report analyzes the key forces that are shaping the present state of the competitive landscape of the market, including threat of substitutes and new entrants, degree of competition, and bargaining power of suppliers and buyers. The key players in the market are profiled in detail based on attributes such as recent developments, company portfolio, business strategies, financial overview, and market share.
Companies Profiled in the Report
Some of the key players operating in the global protein therapeutics market profiled in the report are Johnson & Johnson, Eli Lilly & Company, Roche Group, Pfizer, Inc., Bristol Myers Squibb Co., Sanofi, Merck Sereno S.A. Amgen, Inc., and Novartis.